Gan & Lee Pharmaceuticals. reported earnings results for the nine months ended September 30, 2022. For the nine months, the company reported sales was CNY 1,236.89 million compared to CNY 2,503.07 million a year ago.

Revenue was CNY 1,236.89 million compared to CNY 2,503.07 million a year ago. Net loss was CNY 413.81 million compared to net income of CNY 871.41 million a year ago. Basic loss per share from continuing operations was CNY 0.74 compared to basic earnings per share from continuing operations of CNY 1.55 a year ago.

Diluted loss per share from continuing operations was CNY 0.74 compared to diluted earnings per share from continuing operations of CNY 1.55 a year ago.